| A data monitoring committee found no serious safety concerns with the vaccine, which requires two doses. The pharmaceutical giant and its German partner, BioNTech, said they intend to seek emergency authorization after the third week of November for the vaccine, one of four in the last stages of testing in the United States. | 
No comments:
Post a Comment